Abstract
The three Pim kinases are a small family of serine/threonine kinases regulating several signaling pathways that are fundamental to cancer development and progression. They were first recognized as pro-viral integration sites for the Moloney Murine Leukemia virus. Unlike other kinases, they possess a hinge region which creates a unique binding pocket for ATP. Absence of a regulatory domain means that these proteins are constitutively active once transcribed. Pim kinases are critical downstream effectors of the ABL (ableson), JAK2 (janus kinase 2), and Flt-3 (FMS related tyrosine kinase 1) oncogenes and are required by them to drive tumorigenesis. Recent investigations have established that the Pim kinases function as effective inhibitors of apoptosis and when overexpressed, produce resistance to the mTOR (mammalian target of rapamycin) inhibitor, rapamycin . Overexpression of the PIM kinases has been reported in several hematological and solid tumors (PIM 1), myeloma, lymphoma, leukemia (PIM 2) and adenocarcinomas (PIM 3). As such, the Pim kinases are a very attractive target for pharmacological inhibition in cancer therapy. Novel small molecule inhibitors of the human Pim kinases have been designed and are currently undergoing preclinical evaluation.
Keywords: Akt, cell signalling, drug development, kinase, mTOR, PI3 kinase, PIM kinase, cancer, targeted therapies, pharmacokinetics
Current Drug Targets
Title: The Pim Kinases: New Targets for Drug Development
Volume: 12 Issue: 14
Author(s): Ronan Swords, Kevin Kelly, Jennifer Carew, Stefan Nawrocki, Devalingam Mahalingam, John Sarantopoulos, David Bearss and Francis Giles
Affiliation:
Keywords: Akt, cell signalling, drug development, kinase, mTOR, PI3 kinase, PIM kinase, cancer, targeted therapies, pharmacokinetics
Abstract: The three Pim kinases are a small family of serine/threonine kinases regulating several signaling pathways that are fundamental to cancer development and progression. They were first recognized as pro-viral integration sites for the Moloney Murine Leukemia virus. Unlike other kinases, they possess a hinge region which creates a unique binding pocket for ATP. Absence of a regulatory domain means that these proteins are constitutively active once transcribed. Pim kinases are critical downstream effectors of the ABL (ableson), JAK2 (janus kinase 2), and Flt-3 (FMS related tyrosine kinase 1) oncogenes and are required by them to drive tumorigenesis. Recent investigations have established that the Pim kinases function as effective inhibitors of apoptosis and when overexpressed, produce resistance to the mTOR (mammalian target of rapamycin) inhibitor, rapamycin . Overexpression of the PIM kinases has been reported in several hematological and solid tumors (PIM 1), myeloma, lymphoma, leukemia (PIM 2) and adenocarcinomas (PIM 3). As such, the Pim kinases are a very attractive target for pharmacological inhibition in cancer therapy. Novel small molecule inhibitors of the human Pim kinases have been designed and are currently undergoing preclinical evaluation.
Export Options
About this article
Cite this article as:
Swords Ronan, Kelly Kevin, Carew Jennifer, Nawrocki Stefan, Mahalingam Devalingam, Sarantopoulos John, Bearss David and Giles Francis, The Pim Kinases: New Targets for Drug Development, Current Drug Targets 2011; 12 (14) . https://dx.doi.org/10.2174/138945011798829447
DOI https://dx.doi.org/10.2174/138945011798829447 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent
Current Topics in Medicinal Chemistry Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Blood Stem Cells and non-Hematological Clinical Practice: Pragmatics Before Therapeutics
Current Pharmaceutical Biotechnology Mevalonate-Ras Homology (Rho)/Rho-Associated Coiled-Coil-Forming Protein Kinase (ROCK)-Mediated Signaling Pathway as a Therapeutic Target for the Treatment of Endometriosis-Associated Fibrosis
Current Signal Transduction Therapy Engineering Approaches to Develop the Next Generation of Antibodies to Respiratory Targets
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Tumor Necrosis Factor-α in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Surface Modification: Approaches and Utilities
Current Applied Polymer Science Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Emerging Breast Cancer Biomarkers
Current Cancer Therapy Reviews Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued)